MX2022011233A - Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas. - Google Patents

Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.

Info

Publication number
MX2022011233A
MX2022011233A MX2022011233A MX2022011233A MX2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A MX 2022011233 A MX2022011233 A MX 2022011233A
Authority
MX
Mexico
Prior art keywords
compositions
methods
vitamins
high concentrations
eye diseases
Prior art date
Application number
MX2022011233A
Other languages
English (en)
Inventor
Daniel J Stein
Melinda Divito
Lester Hosten
Original Assignee
Bausch & Lomb Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Ireland Ltd filed Critical Bausch & Lomb Ireland Ltd
Publication of MX2022011233A publication Critical patent/MX2022011233A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción describe composiciones que comprenden un potente complejo de vitaminas B y sales farmacéuticamente aceptables de cualquiera de los anteriores. Las composiciones son útiles en métodos para tratar afecciones asociadas con una pérdida de agudeza visual que incluyen, por ejemplo, degeneración macular relacionada con la edad.
MX2022011233A 2020-03-11 2021-03-10 Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas. MX2022011233A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988375P 2020-03-11 2020-03-11
US202063045585P 2020-06-29 2020-06-29
PCT/IB2021/052005 WO2021181309A1 (en) 2020-03-11 2021-03-10 Compositions and methods for age related eye diseases comprising high concentrations of vitamins

Publications (1)

Publication Number Publication Date
MX2022011233A true MX2022011233A (es) 2022-12-13

Family

ID=74874915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011233A MX2022011233A (es) 2020-03-11 2021-03-10 Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.

Country Status (10)

Country Link
US (1) US20230117576A1 (es)
EP (1) EP4117649A1 (es)
JP (1) JP2023533632A (es)
KR (1) KR20220152231A (es)
CN (1) CN115515574A (es)
AU (1) AU2021233236A1 (es)
BR (1) BR112022018109A2 (es)
CA (1) CA3175093A1 (es)
MX (1) MX2022011233A (es)
WO (1) WO2021181309A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3175074A1 (en) * 2020-03-11 2021-09-16 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising areds and vitamin b complex

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
JP2004515508A (ja) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
US6953588B2 (en) * 2002-10-25 2005-10-11 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US20080063730A9 (en) * 2004-07-29 2008-03-13 Giordano John A Methods for prophylactic and therapeutic nutritional supplementation
JP2008520576A (ja) * 2004-11-16 2008-06-19 ニュー‐ティーン カンパニー，インク． 眼性血管新生症および黄斑変性の処置に有用な組成物
CA2633868A1 (en) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
JP2010538674A (ja) * 2007-09-19 2010-12-16 オフサルモファーマ・アクチェンゲゼルシャフト 栄養補助剤およびそのような補助剤を含む強化食品
US20110142766A1 (en) * 2009-12-16 2011-06-16 Sal Rafanelli Effervescent Multi-Vitamin Formulation and Methods of Use Thereof
CA2837047C (en) * 2011-07-07 2019-04-23 Howard Foundation Holdings Ltd Improvements in or relating to visual performance and/or macular pigmentation
TW201406382A (zh) * 2012-08-09 2014-02-16 Tci Co Ltd 具視網膜保護功能之複方組成物及應用
CN103340891A (zh) * 2013-06-08 2013-10-09 哈尔滨珍宝制药有限公司 一种含b族维生素的组合物及其制备方法
CN108606199A (zh) * 2018-03-27 2018-10-02 佛山市体视能饮料有限公司 一种可缓解体力和视力疲劳的功能性饮料及其制备方法
AU2019328475B2 (en) * 2018-08-29 2023-02-16 Dsm Ip Assets B.V. Formulations for improving gut health
CA3175074A1 (en) * 2020-03-11 2021-09-16 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising areds and vitamin b complex

Also Published As

Publication number Publication date
US20230117576A1 (en) 2023-04-20
CN115515574A (zh) 2022-12-23
JP2023533632A (ja) 2023-08-04
KR20220152231A (ko) 2022-11-15
AU2021233236A1 (en) 2022-09-15
BR112022018109A2 (pt) 2022-11-08
CA3175093A1 (en) 2021-09-16
WO2021181309A1 (en) 2021-09-16
EP4117649A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
EP4360709A3 (en) Use of a vegf antagonist to treat angiogenic eye disorders
WO2012158910A3 (en) Compositions and methods for treating retinal diseases
TN2009000241A1 (en) Nutritional supplement composition for treatment of ocular diseases
MX2021007709A (es) Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
HK1220871A1 (zh) 含有RRRα-生育酚的婴儿营养产品
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
NZ799504A (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
MX2022011233A (es) Composiciones y metodos para enfermedades oculares relacionadas con la edad que comprenden altas concentraciones de vitaminas.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2025007818A (es) Composiciones que comprenden coenzima q10 y su uso para el tratamiento de trastornos oculares y cardiacos
MX2022011235A (es) Composiciones y metodos para la salud ocular que comprenden areds y complejo de vitamina b.
MX2021008821A (es) Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
NZ757557A (en) Methods of preventing or treating ophthalmic diseases
BR112022018122A2 (pt) Composições e métodos para saúde ocular compreendendo ácidos gordos de cadeia muito longa
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
PH12022550003A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
Beatty et al. Visual outcome after antioxidant supplementation
CN105456239A (zh) 一种虾青素和叶黄素组合物及其用途
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.